RNS Number : 0619I

OptiBiotix Health PLC

10 August 2021

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

Extension of territories for Seed Health's DS-01 product

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, a nn o unces that its wholly-owned subsidiary, ProBiotix Health Ltd, has extended the territories of its original agreement (RNS: 22 May 2018) with Seed Health, Inc. ('Seed(TM) ') for the production, promotion, marketing and commercialisation of products containing LP(LDL) (R). The agreement extends the territories from the USA, to include the countries within Europe, Oceania (e.g. Australia, New Zealand etc), and Asia (excluding India) for the supply of LP(LDL) (R) in Seed(TM') s DS-01 product, a multi-strain synbiotic product which contains OptiBiotix's Lactobacillus plantarum LP(LDL) (R). DS-O1 received FDA authorisation for an Investigational New Drug ("IND") in October 2020 (RNS: 2 October 2020) for IBS applications.

Seed(TM) ( seed.com ) was co- founded by Raja Dhir and Ara Katz to pioneer the development of next-generation probiotic and live biotherapeutic applications and recently closed a $40m Series A funding round to fund new category launches and international expansion. This agreement supports the Seed(TM) expansion plans for DS-01 and is another example of OptiBiotix's partners either extending their product range (e.g. Optipharm, Holland and Barrett) or, as in this case, taking existing products into new territories. This extension will contribute to growing the Group's recurring revenue and demonstrates the effectiveness of the Company's strategy of diversifying routes to market through multiple partnership agreements.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to strengthen our already strong relationship with Seed Health by agreeing this territory expansion for DS-01 to support their ambitious growth plans. This is another example of OptiBiotix's partners extending their product range or expanding existing products into new territories. This helps to grow the existing recurring revenue base and provides a solid foundation on which to build a valuable and sustainable business."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 OptiBiotix Health plc                             www.optibiotix.com 
 Neil Davidson, Chairman                         Contact via Walbrook 
 Stephen O'Hara, Chief Executive 
 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 Cenkos Securities plc (Broker)                    Tel: 020 7397 8900 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 Walbrook PR Ltd                                   Mob: 07876 741 001 
 Anna Dunphy 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi ed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

August 10, 2021 02:00 ET (06:00 GMT)

Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Optibiotix Health Charts.
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Optibiotix Health Charts.